Latest Articles
07. 07. 2014
Posting of clinical trial summary results in European Clinical Trials Database (EudraCT) to become mandatory
State Institute for Drug Control announces that the posting of summaries of clinical study results in the European Clinical Trials Database (EudraCT) becomes mandatory as...
03. 07. 2014
Correction of the List of reimbursed medicinal products valid as of 3.7.2014
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
30. 06. 2014
List of reimbursed medicinal products valid as of 1.7.2014
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
17. 06. 2014
Submission of Documentation via the CESP Portal
The State Institute for Drug Control (hereinafter referred to as the "Institute") hereby informs about the possibility to submit authorisation applications and related...
13. 06. 2014
Correction of the List of reimbursed medicinal products valid as of 13.6.2014
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
10. 06. 2014
Centralised Procedure Documentation – change in submission to Czech NCA
The introduction of the Common Repository in February 2014 by European Medicines Agency has enabled Czech NCA to use the system as the only source of Centralised Procedure...
30. 05. 2014
List of reimbursed medicinal products valid as of 1.5.2014
Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List of...
27. 05. 2014
Overview of documents, which are approved/acknowledged/left without any feedback by Institute on the field of Clinical Trials
Overview of possible ways of response of Institute to documents, which are submitted during Clinical Trial of human medicinal products to Clinical Trials Dpt.
cz
